Mankind Pharma is among the pharmaceutical companies affected after the Union health and family welfare ministry restricted manufacture, sale and distribution of fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride for children below four years, requiring a warning label and barring marketing for infant use.

Mankind Pharma Limited is among the Indian drugmakers that launched cheaper semaglutide versions after the global patent expired on 20 March, and will now be subject to the Indian Pharmacopoeia Commission's forthcoming legally binding monograph that sets uniform purity, potency and impurity limits for semaglutide.

Mankind Pharma Ltd has entered an exclusive in-licensing and marketing agreement with China's Chongqing Chenan Biopharmaceutical Co Ltd to commercialise insulin degludec and insulin degludec as part of a combination in India, which Mankind Pharma said will enhance its position and portfolio in the injectable diabetes segment.